Do Alzheimer’s sufferers finally have cause for optimism? | Tom Solomon

There's no treatment that actually tackles the underlying causes of this terrible disease. Solanezumab, a genetically engineered antibody, may be the first

Every week in my neurology clinic at the Walton Neuro-Centre in Liverpool, I see people who are worried that they may have Alzheimer's disease. Perhaps this is not surprising, given there is a news story about the disease almost daily, an estimated 850,000 people in the UK have dementia, and the government has described it as "one of the greatest challenges of our lifetime". This is why news of solanezumab, a drug that appears to slow decline in Alzheimer's patients, has provoked such interest.

Currently, the treatments we can offer patients with Alzheimer's disease are very limited